Enanta Pharmaceuticals has linked its respiratory syncytial virus (RSV) antiviral to significant reductions in viral load and ...
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV ...
Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...
In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), ...
Enanta Pharmaceuticals announced positive topline results from a Phase IIa trial of EDP-323, its RSV replication inhibitor, ...
Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday. The ...
On Friday, Baird maintained its Outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA), with a steady price target of $26.00. This decision follows the release of new data related to ...
On Friday, Baird maintained its Outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA), with a steady price target of $26.00. This decision follows the release of new data related to ...
Watertown, Massachusetts Saturday, September 28, 2024, 18:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback